Search the Newsreel

Oncology Institute, Inc. (TOI) awards 31,124 RSUs to board director

Oncology Institute, Inc. (TOI) director Mark Stolper has been granted 31,124 restricted stock units (RSUs) as equity compensation. These RSUs, granted at $0.00 per share, vest in full on the date of the company's 2027 annual meeting of stockholders, provided Stolper continues his service. …

Citius Oncology Inc (CTOR) Financial Health: Profitability & Balance Sheet Analysis

Citius Oncology Inc (CTOR) currently holds a financial score of 7.83, placing it 79th out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The report notes that relevant financial data for key metrics like …

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

Kura Oncology announced encouraging and durable clinical activity results from its FIT-001 clinical trial for darlifarnib plus cabozantinib in cabozantinib-naïve clear cell renal cell carcinoma patients. The study showed objective response rates up to 50% and a median progression-free survival of 13 months, with …

Champions Oncology Inc (CSBR) Financial Health: Profitability & Balance Sheet Analysis

Champions Oncology Inc (CSBR) currently has a financial score of 8.72, ranking 31st out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 2.82% year-over-year to 16.56M, while …

ALXO|ALX Oncology Holdings Inc|Price:1.950|Chg%:-0.040

This article provides a comprehensive stock analysis of ALX Oncology Holdings Inc (ALXO), highlighting its relatively weak fundamentals but high growth potential and fair valuation within the Biotechnology & Medical Research industry. The company's lead product candidate, evorpacept, is a CD47 blocking therapeutic, and …

Law firm investigates CG Oncology officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating officers and directors of CG Oncology, Inc. for potential breaches of fiduciary duties through self-dealing. This probe could result in damages for shareholders and corporate governance reforms, and long-term shareholders are encouraged to contact the law firm.

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled …

Oncology Institute, Inc. (TOI) grants RSU equity award to director

Oncology Institute, Inc. (TOI) director Anne McGeorge received a grant of 41,165 restricted stock units (RSUs). These RSUs vest in full on the date of the company's 2027 annual meeting of stockholders, contingent on her continued service. Following this award, her direct holdings in …

Oncology Institute (NASDAQ: TOI) awards 30,120 RSUs to director

Oncology Institute director Mark L. Pacala was granted 30,120 restricted stock units (RSUs), increasing his direct holdings to 286,881 shares. These RSUs will vest in full at the company's 2027 annual meeting of stockholders, contingent upon his continued service. This transaction was reported in …

Concord Medical Services Holdings Ltd

The article provides a brief overview of Concord Medical Services Holdings Ltd (CCM), including its stock price and market capitalization. It indicates that relevant data regarding the company's revenue breakdown by business segment and region has not yet been disclosed. The page highlights the …

Kura Oncology (NASDAQ: KURA) revises CEO and executive severance

Kura Oncology (NASDAQ: KURA) has revised the employment agreements for its CEO, CCO, and COO to update severance and change-of-control protections. These new terms define cash severance, COBRA coverage, equity vesting, and stock option exercise rights, differentiating based on whether a termination is linked …

CGON (CGON) insider files to sell 4,303 shares after option exercise

An insider at CG Oncology, Inc. (CGON) has filed a Form 144 notice to sell 4,303 common shares after exercising stock options on July 29, 2026. This sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also details …

ALX Oncology Holdings Inc (ALXO) Financial Health: Profitability & Balance Sheet Analysis

The article analyzes the financial health of ALX Oncology Holdings Inc (ALXO), noting its weak financial status and low operating efficiency with a score of 5.40 out of 385 in the Biotechnology & Medical Research industry. It highlights that relevant financial data for Quality …

BridgeBio Oncology Therapeutics Inc. (BBOT) Q1 2026 Earnings: Narrower-Than-Expected Loss but Shares Slide Amid Pre-Revenue Status - Banking Earnings Report

Oncology Institute Inc (TOI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Oncology Institute Inc (TOI), noting its current valuation score of 7.50, ranking 52 out of 75 in its industry. The company's current P/E ratio is -13.88, which is significantly below its recent high and above its recent …

Liquidity Mapping Around (CGEM) Price Events

This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies key support and resistance levels, offering three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. …

CGON (CGON) insider Ambaw Bellete files to sell 50,000 shares

Ambaw Bellete, an insider at CG Oncology, Inc. (CGON), has filed a Form 144 indicating an intention to sell 50,000 shares of common stock. This planned sale, valued at approximately $3.6 million, is scheduled for on or after July 28, 2026, and is connected …

LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $108

LifeSci Capital has reiterated its Buy rating on CG Oncology (CGON.US) and maintained its target price of $108. This indicates continued confidence from the firm in the company's prospects.

ALX Oncology Holdings Inc. $ALXO Stock Position Boosted by venBio Partners LLC

venBio Partners LLC significantly increased its stake in ALX Oncology Holdings Inc. ($ALXO) by 32.8% in Q1, acquiring over 3.18 million additional shares. This makes ALXO the third-largest holding in venBio's portfolio, representing 9.58% of ALXO's total shares. Despite the company missing its latest …

Is Aktis Oncology (AKTS) Fairly Valued After Its Recent Pullback?

Aktis Oncology (AKTS) stock has experienced a recent pullback, dropping 4% in the past week and 17% in the last month, despite year-to-date gains. The company, which focuses on radiopharmaceutical research, trades at a Price-to-Book (P/B) ratio of 2.6x, slightly above the US Biotech …

A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40

This article provides a quick look at analyst ratings for Kura Oncology (KURA.US). Forecasts for the company's stock price range from $28 to $40. Investors are encouraged to consider these ratings as part of a broader investment strategy.

ONCY|Oncolytics Biotech Inc|Price:0.750|Chg%:-0.042

This article provides a comprehensive stock analysis of Oncolytics Biotech Inc (ONCY), highlighting its healthy fundamentals, high growth potential, and "Buy" ratings from multiple analysts despite a recent weak stock market performance. The company is developing pelareorep, an immunotherapeutic agent for various cancers, and …

KURA Reiterates by Wedbush -- Price Target Maintained at $36

Wedbush has reiterated an "Outperform" rating for Kura Oncology (KURA) and maintained a price target of $36.00, signaling confidence despite the company's low GF Score™ of 28/100, which highlights profitability and growth challenges. Insider activity, marked by $1.0 million in net selling and no …

Kura Oncology Reports 50% Response Rate in RCC Combination Study

Kura Oncology announced promising updated results from its Phase 1 FIT-001 trial, showing a 50% objective response rate in cabozantinib-naive clear cell RCC patients treated with darlifarnib and cabozantinib. The combination therapy demonstrated a manageable safety profile, with neutropenia being the most notable adverse …

For AML patients with limited options, Cullinan plans a new study

Cullinan Therapeutics received positive feedback from the FDA for its FLT3xCD3 T cell engager CLN-049 in acute myeloid leukemia (AML), paving the way for a potentially registrational Phase 2 study in Q3 2026. The study will focus on relapsed/refractory AML, an area with limited …

Why is Cullinan Therapeutics stock climbing today?

Cullinan Therapeutics (CGEM) stock rose in pre-open trading after receiving positive FDA feedback for CLN-049, a drug for relapsed/refractory acute myeloid leukemia. The company plans to initiate a potentially registrational Phase 2 study in Q3 2026, which investors view as an accelerated path to …

Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.

Champions Oncology, Inc. provided a tranche update on its equity buyback plan announced on April 5, 2023. From February 1, 2026, to April 30, 2026, the company did not repurchase any shares. However, since the plan's inception, the company has completed the repurchase of …

BridgeBio Oncology Therapeutics, Inc. Revenue Breakdown – NASDAQ:BBOT

The article focuses on BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) and its revenue breakdown, accessible through TradingView's financial section. It provides an overview of market data, fundamentals, and statistics for the company. The content appears to be a stub or a navigation page within …

ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for ALX Oncology Holdings Inc (ALXO), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It displays current stock information including the market cap and P/E TTM. …

CTOR Q2 2026 Earnings: Significant EPS Miss Highlights Ongoing Development Stage - Non-GAAP Earnings

CG Oncology Inc. (CGON) Experiences Modest Pullback as Shares Trade Near Support - Cash Secured Put

Champions Oncology Inc. (CSBR) Slides 8.75% as Selling Pressure Intensifies - NHNL Ratio

Cardiff Oncology (NASDAQ:CRDF) Shares Up 1.1% - Should You Buy?

Insider Buying: Oncology Institute (NASDAQ:TOI) Major Shareholder Buys 18,000 Shares

Cardiff Oncology (CRDF) Expected to Post Quarterly Earnings on Tuesday

OncoSil Medical Slips as Its Pancreatic Cancer Device Reaches the FDA's Door